Mike currently serves as Chairman of Mirum Pharmaceuticals (NASDAQ: MIRM), as Executive Chair of Plexium, Sorriso Pharmaceuticals, Spruce Biosciences and Reneo Pharmaceuticals (a Pappas Ventures V portfolio company), and as a director for Horizon Therapeutics (NASDAQ: HZNP). In 2011, he spearheaded the founding of Lumena Pharmaceuticals, and served as CEO until it was acquired by Shire plc in 2014. Prior to Lumena, Mike was President and CEO of SGX Pharmaceuticals until its sale to Eli Lilly. Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma, from 1994 to 1998. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President of Corporate Development and head of worldwide business development. Mike previously served as CEO and subsequently Executive Chair of Amplyx Pharmaceuticals which was acquired by Pfizer. He also previously served as a director for BioMarin Pharmaceutical (NASDAQ: BMRN), Mirati Therapeutics (NASDAQ: MRTX), Balance Therapeutics, Selventa, Biothera Pharmaceutical, Ziarco Pharma (acquired by Novartis), and three public companies, SGX Pharmaceuticals, IDM Pharma and Achillion Pharmaceuticals.